Please Wait.....
Report
Stem Cell - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)
Market Report I 2025-06-01 I 118 Pages I Mordor Intelligence
Stem Cell Market Analysis
The stem cell market stands at USD 17.13 billion in 2025 and is projected to reach USD 29.88 billion by 2030, advancing at an 11.77% CAGR. Growth is unfolding on several fronts: newly approved mesenchymal stromal cell therapies have shortened commercial lead times, investment is pouring into induced pluripotent stem cell (iPSC) platforms, and specialized CDMOs are scaling manufacturing capacity. Accelerated regulatory pathways, especially in the United States and Japan, are bringing therapies to patients sooner, while CRISPR-enabled editing and AI-guided production workflows are lifting product quality and broadening therapeutic scope. Regional momentum is shifting toward Asia-Pacific, where national policies are positioning stem cells as strategic technologies. Competitive intensity is increasing as large biopharma acquires innovators to secure delivery tools that ease in-vivo administration.
Global Stem Cell Market Trends and Insights
High Burden of Chronic and Degenerative Diseases
Aging demographics are magnifying demand for regenerative options. Parkinson's disease is forecast to affect 25.2 million people by 2050, with population aging driving 89% of the increase.Mesenchymal stem cells (MSCs) reduce inflammation, inhibit tissue breakdown, and spur repair, positioning them as cost-effective tools for chronic disease management. Health systems are reallocating budgets toward therapies that can defer expensive long-term care, reinforcing procurement of MSC-based products and fortifying the stem cell market.
Rapidly Expanding Regenerative-Medicine Pipeline
More than 4,000 gene, cell, and RNA therapies are in development, and Phase I programs climbed 11% in early 2024. CRISPR editing is boosting CAR-T performance and opening autoimmune indications. AI-enabled analytics now automate cell phenotyping, trimming release testing from days to hours. Clinical evidence is broadening: retinal cell transplants restored meaningful visual acuity, and iPSC-derived constructs demonstrated promising glycemic control in type 1 diabetes. These advances expand addressable populations, lifting the stem cell market outlook.
Safety and Efficacy Uncertainties
Tumorigenicity and immunogenicity remain central concerns for pluripotent cell types. Batch variability complicates potency assays, prompting regulators to reinforce oversight. Research groups have engineered immune-cloaked grafts that evade NK-cell detection while integrating into host tissue. A Ninth Circuit ruling affirming FDA authority over cell therapies clarifies compliance obligations but may lengthen timelines.
Other drivers and restraints analyzed in the detailed report include:
Favorable Regulatory Acceleration Pathways / Rising Penetration of Cord-Blood/Tissue Banking / Restrictive Reimbursement Policies /
For complete list of drivers and restraints, kindly check the Table Of Contents.
Segment Analysis
Adult stem cells held 55.0% of stem cell market share in 2024 owing to a well-documented safety record and broad therapeutic latitude. MSC-specific quality control guidelines now standardize potency assays, supporting widespread clinical use. The stem cell market size for adult stem-cell products is projected to grow steadily as orthopedic, cardiac, and immunological programs mature. Conversely, iPSCs are advancing at a 10.43% CAGR, propelled by improved reprogramming efficiency and expanding GMP capacity. Aspen Neuroscience automated production of ANPD001 for Parkinson's disease in January 2025, demonstrating how closed-system workflows can compress autologous lead times. VSELs are gaining attention for multi-lineage potential without teratoma risk frontiersin.org. Investor focus is shifting toward off-the-shelf iPSC lines engineered for immune evasion, indicating sustained capital inflows through 2030.
Advances in cryoprotectant cocktails are reducing post-thaw apoptosis, enhancing viability across both adult and iPSC derivatives. Regulatory bodies encourage harmonized release specifications, which will gradually narrow the cost gap between the two product classes. As these innovations integrate into routine practice, the stem cell market will likely see convergence in use cases, particularly where personalized therapies must scale quickly.
Orthopedic indications represented 23.0% of the stem cell market size in 2024, anchored by evidence that MSC injections improve pain scores in osteoarthritis and promote spinal fusion. MSC therapy recorded the highest pain-reduction coefficient among regenerative orthopedic options.The segment remains resilient as an aging population drives demand for joint repair. Neurological disorders, however, are on track to grow at an 11.23% CAGR. Progress in dopaminergic neuron replacement has yielded measurable motor gains in Parkinson's cohorts. Enhanced blood-brain barrier crossing techniques and immune-cloaked cell lines are widening the clinical pipeline for Alzheimer's disease and stroke. Cardiovascular programs are similarly expanding; Cellipont's cGMP partnership targets cardiac progenitor cell supply.
Clinical trial diversity is rising. Hematologic cancers continue to anchor transplant volumes, while beta-cell replacement for diabetes is entering Phase II evaluation. Together, these trends reinforce a balanced application mix, supporting continuous revenue growth across the stem cell market.
The Stem Cells Market is Segmented by Product Type (Adult Stem Cell, Human Embryonic Cell, Induced Pluripotent Stem Cell, and More), Application (Neurological Disorders, Orthopedic Treatments, and More), Treatment Type (Allogeneic Stem Cell Therapy and More), End User (Academic and Research Institutes, Hospitals and Surgical Centers and More) and Geography. The Market and Forecasts are Provided in Terms of Value (USD).
List of Companies Covered in this Report:
ATCC / Thermo Fisher Scientific / Merck / Stem Cell Technologies / Takara Bio / Miltenyi Biotec / Pluri Inc. / AllCells / International Plastics / ReNeuron Group / Bio-Techne Corp. / Gamida Cell Ltd. / Fate Therapeutics Inc. / Cynata Therapeutics / BioRestorative Therapies Inc. / BrainStorm Cell / Lineage Cell Therapeutics / Regenexx LLC / Orchard Therapeutics plc / Mesoblast / Athersys / Medipost Co. Ltd. / PromoCell /
Additional Benefits:
The market estimate (ME) sheet in Excel format /
3 months of analyst support /
1 Introduction
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Burden of Chronic and Degenerative Diseases
4.2.2 Rapidly Expanding Regenerative-Medicine Pipeline
4.2.3 Favorable Regulatory Acceleration Pathways
4.2.4 Rising Penetration of Public and Private Cord-blood/Tissue Banking and Personalized-Medicine Programs
4.2.5 Technology Breakthroughs Enabling Off-the-Shelf Therapies
4.2.6 Intesifying Colloboration Among Market Players for Innovation and Development in The Field
4.3 Market Restraints
4.3.1 Safety and Efficacy Uncertainties Associated with Therapies
4.3.2 Restrictive Reimbursement Policies
4.3.3 Manufacturing Scale Challenges and High Cost of Products and Procedures
4.3.4 Ethical and Policy Divergence Due to Persistent Moral Concerns
4.4 Value / Supply-Chain Analysis
4.5 Regulatory Outlook
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Threat of New Entrants
4.7.2 Bargaining Power of Buyers
4.7.3 Bargaining Power of Suppliers
4.7.4 Threat of Substitutes
4.7.5 Intensity of Competitive Rivalry
5 Market Size and Growth Forecasts (Value-USD)
5.1 By Product Type
5.1.1 Adult Stem Cells
5.1.1.1 Mesenchymal Stem Cells
5.1.1.2 Hematopoietic Stem Cells
5.1.1.3 Neural Stem Cells
5.1.2 Human Embryonic Stem Cells
5.1.3 Induced Pluripotent Stem Cells (iPSCs)
5.1.4 Very Small Embryonic-like Stem Cells
5.1.5 Other Product Types (e.g., Cancer Stem Cells)
5.2 By Application
5.2.1 Neurological Disorders
5.2.2 Orthopedic Treatments
5.2.3 Oncology Disorders
5.2.4 Cardiovascular and Myocardial Infarction
5.2.5 Diabetes and Metabolic Disorders
5.2.6 Wounds and Burns
5.2.7 Other Applications
5.3 By Treatment Type
5.3.1 Allogeneic Stem Cell Therapy
5.3.2 Autologous Stem Cell Therapy
5.3.3 Syngeneic Stem Cell Therapy
5.4 By End User
5.4.1 Academic & Research Institutes
5.4.2 Hospitals and Surgical Centers
5.4.3 Pharmaceutical and Biotechnology Companies
5.4.4 Stem Cell Banks and Cryopreservation Facilities
5.4.5 Contract Development and Manufacturing Organizations (CDMOs)
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 South Korea
5.5.3.5 Australia
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East & Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East & Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Strategic Moves
6.3 Market Share Analysis
6.4 Company profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
6.4.1 ATCC
6.4.2 Thermo Fisher Scientific Inc.
6.4.3 Merck KGaA
6.4.4 STEMCELL Technologies
6.4.5 Takara Bio Inc.
6.4.6 Miltenyi Biotec
6.4.7 Pluri Inc.
6.4.8 AllCells LLC
6.4.9 International Stem Cell Corp.
6.4.10 ReNeuron Group plc
6.4.11 Bio-Techne Corp.
6.4.12 Gamida Cell Ltd.
6.4.13 Fate Therapeutics Inc.
6.4.14 Cynata Therapeutics Ltd
6.4.15 BioRestorative Therapies Inc.
6.4.16 BrainStorm Cell Therapeutics
6.4.17 Lineage Cell Therapeutics
6.4.18 Regenexx LLC
6.4.19 Orchard Therapeutics plc
6.4.20 Mesoblast Ltd
6.4.21 Athersys Inc.
6.4.22 Medipost Co. Ltd.
6.4.23 PromoCell GmbH
7 Market Opportunities and Future Outlook
7.1 White-space and Unmet-Need Assessment
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security